Group 1 - The core viewpoint of the article is that Citigroup maintains a positive outlook on Ark Health (06086), rating it as "Buy" with a target price of HKD 8.5 [1] - Ark Health has released a positive earnings forecast, expecting revenue between RMB 3.5 billion and RMB 3.55 billion for the previous year, representing a year-on-year growth of 30% [1] - The company anticipates turning a profit, with expected earnings between RMB 7 million and RMB 10 million [1] Group 2 - Citigroup believes that Ark Health's performance is generally in line with expectations, having previously predicted a 28% revenue growth for 2025 and a net profit of RMB 6 million [1] - Management attributes the rapid revenue growth to an increase in the number of patients and doctors on the platform, while the return to profitability is mainly due to revenue expansion and a reduction in share-based expenses [1] - On the morning of the 26th, Ark Health opened significantly higher by 10.25%, reaching a peak of HKD 4.19, and closed at HKD 4.01, marking a 41.7% increase with a trading volume of 118 million shares, amounting to HKD 452 million [1]
花旗：方舟健客盈喜符预期 评级“买入”目标价8.5港元